JP7805010B2 - コロナウイルス感染を予防および処置する化合物および方法 - Google Patents

コロナウイルス感染を予防および処置する化合物および方法

Info

Publication number
JP7805010B2
JP7805010B2 JP2022566726A JP2022566726A JP7805010B2 JP 7805010 B2 JP7805010 B2 JP 7805010B2 JP 2022566726 A JP2022566726 A JP 2022566726A JP 2022566726 A JP2022566726 A JP 2022566726A JP 7805010 B2 JP7805010 B2 JP 7805010B2
Authority
JP
Japan
Prior art keywords
sars
cov
coronavirus
compound
3clpro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022566726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524274A5 (https=
JP2023524274A (ja
Inventor
ロ，ジャー－メン
ホアン，チェン
ビー ウー，イェー
ジュー リアン，ホイ
リン，ペイ－シン
チャン，ハオ
チュウ，ウェイ－チョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arjil Biotech Holding Co Ltd
Original Assignee
Arjil Biotech Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arjil Biotech Holding Co Ltd filed Critical Arjil Biotech Holding Co Ltd
Publication of JP2023524274A publication Critical patent/JP2023524274A/ja
Publication of JP2023524274A5 publication Critical patent/JP2023524274A5/ja
Application granted granted Critical
Publication of JP7805010B2 publication Critical patent/JP7805010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022566726A 2020-05-01 2021-04-29 コロナウイルス感染を予防および処置する化合物および方法 Active JP7805010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01
PCT/US2021/029840 WO2021222534A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Publications (3)

Publication Number Publication Date
JP2023524274A JP2023524274A (ja) 2023-06-09
JP2023524274A5 JP2023524274A5 (https=) 2024-06-14
JP7805010B2 true JP7805010B2 (ja) 2026-01-23

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566726A Active JP7805010B2 (ja) 2020-05-01 2021-04-29 コロナウイルス感染を予防および処置する化合物および方法

Country Status (7)

Country Link
US (1) US12433901B2 (https=)
EP (1) EP4142713A1 (https=)
JP (1) JP7805010B2 (https=)
CN (1) CN116568295B (https=)
AU (1) AU2021264554A1 (https=)
TW (1) TW202206080A (https=)
WO (1) WO2021222534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535714A (ja) * 2020-07-23 2023-08-21 アージル・バイオテック・ホールディング・カンパニー・リミテッド ウイルス感染を阻害するための方法および組成物
US20240408055A1 (en) * 2021-10-21 2024-12-12 Peking University Shenzhen Graduate School Use of anisomelic acid in preparation of pharmaceutical composition for inhibiting infection and replication of sars-cov-2 and variants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
FI126047B (en) * 2012-08-28 2016-06-15 John Eriksson Pharmaceutical compositions of anisomelic acid and their use
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
US11253527B2 (en) * 2019-02-25 2022-02-22 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
WO2021202982A1 (en) * 2020-04-03 2021-10-07 Turtle Bear Holdings, Llc Compositions and methods for modulating inflammatory response
CN113521060B (zh) * 2020-04-17 2022-12-06 北京大学深圳研究生院 鱼针草内酯抗新型冠状病毒的用途
TW202200175A (zh) * 2020-04-28 2022-01-01 浩峰生物科技股份有限公司 牛樟芝萃取物(Ant-Ex)減少血管收縮素轉換酶2(ACE-2)蛋白質表現

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Acta Pharmacologica Sinica，2011年，Vol.32，pp.904-911
Appl. Sci.，2019年，Vol.9, 4281，pp.1-15，doi:10.3390/app9204281
Journal of Endocrinological Investigation，2020年04月25日，Vol.43，pp.1141-1147，https://doi.org/10.1007/s40618-020-01266-w

Also Published As

Publication number Publication date
EP4142713A1 (en) 2023-03-08
US12433901B2 (en) 2025-10-07
WO2021222534A1 (en) 2021-11-04
US20210338690A1 (en) 2021-11-04
AU2021264554A1 (en) 2023-01-05
JP2023524274A (ja) 2023-06-09
TW202206080A (zh) 2022-02-16
CN116568295A (zh) 2023-08-08
CN116568295B (zh) 2026-02-13

Similar Documents

Publication Publication Date Title
US12485157B2 (en) Method of treating COVID-19
Chiou et al. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease
Anirudhan et al. Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19
Kumar et al. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors
Kuo et al. Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
Liang Characterization and inhibition of SARS-coronavirus main protease
CN113289018B (zh) 金诺芬等老药及其组合物在抗单正链rna病毒中的应用
KR20220146558A (ko) 항-코로나바이러스에서의 디설피람의 용도
JP7805010B2 (ja) コロナウイルス感染を予防および処置する化合物および方法
Kuo et al. Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus
Ghosh et al. Progress in anti-SARS coronavirus chemistry, biology and chemotherapy
Wu et al. Antiviral drug discovery against SARS-CoV
CN113262224A (zh) 奈非那韦在制备防治新冠肺炎药物中的应用
Sabbah et al. An updated review on betacoronavirus viral entry inhibitors: learning from past discoveries to advance COVID-19 drug discovery
Al Adem et al. 3-chymotrypsin-like protease in SARS-CoV-2
Shuai et al. An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo
JP2023525855A (ja) コロナウイルスによる疾患の治療及び／又は予防のための化合物及びその使用
JP2023540246A (ja) ウイルス感染を予防および処置するための化合物および方法
Singh et al. COVID-19: pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies
Mondal et al. Evaluation of the binding affinity of anti-viral drugs against main protease of SARS-CoV-2 through a molecular docking study
Zhao et al. Drug targets for rational design against emerging coronaviruses
US11986478B2 (en) Targeting papain-like protease for broad-spectrum coronaviruses inhibition
TWI917417B (zh) 治療病毒感染之方法及組合物
EP4509503A1 (en) Compound and application thereof in preparation of medicine for treating enterovirus-related diseases
JP2023535714A (ja) ウイルス感染を阻害するための方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260105

R150 Certificate of patent or registration of utility model

Ref document number: 7805010

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150